Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

Annals of Oncology

Volumn 12, Issue 2, 2001, Pages 259-266

  Brada, M ^a   Hoang Xuan, K ^b   Rampling, R ^c   Dietrich, P Y ^d   Dirix, L Y ^e   Macdonald, D ^f   Heimans, J J ^g   Zonnenberg, B A ^h   Bravo Marques, J M ⁱ   Henriksson, R ^j   Stupp, R ^k   Yue, N ^l   Bruner, J ^m   Dugan, M ⁿ   Rao, S ⁿ   Zaknoen, S ⁿ  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f LONDON REGIONAL CANCER PROGRAM   (Canada)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^j UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^k Centre Pluralistique d'Oncologie   (Switzerland)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m UNIVERSITY OF TEXAS   (United States)

ⁿ MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Chemotherapy; Glioblastoma multiforme; Gliosarcoma; Quality of life; Temozolomide; Tumor response

Indexed keywords

ANTINEOPLASTIC AGENT; GADOLINIUM; NITROSOUREA; TEMOZOLOMIDE;

ADULT; AGED; ALOPECIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLIOSARCOMA; HEADACHE; HISTOLOGY; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SKIN TOXICITY; STATISTICS; SURVIVAL RATE; THROMBOCYTOPENIA; THRUSH; TUMOR RECURRENCE;

EID: 0035108398     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008382516636     Document Type: Article

References (34)

1. Treatment of recurrent high grade astrocytoma: Results of a systematic review of 1415 patients
2. Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure
3. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas
4. Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA)
5. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors
6. al. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure
7. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen
8. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: A phase II study
9. Fotemustine (F) and cisplatin (P) association in patients with recurrent malignant glioma
10. Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine - A phase II study
11. Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas
12. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results
13. Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas
14. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology
15. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma
16. Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity
17. Potentiation of temozolomide and BCNU cytotoxicity by 0-6-benzylguanine: A comparative study in vitro
18. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
19. The Charing Cross Hospital experience with temozolomide in patients with gliomas
20. Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status
21. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
22. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
23. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas
24. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications
25. Response criteria for phase II studies of supratentorial malignant glioma
26. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement
27. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme
28. Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours
29. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
30. Multicenter CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
31. Clinical trial end points in malignant glioma: Need for effective trial design strategy
32. Malignant glioma: Should chemotherapy be overthrown by experimental treatments?
33. Chemotherapy for brain tumors
34. Nitrosoureas: A reappraisal of clinical trials